Further evidence of the clinical value of CDK12 was provided by the analysis of three independent cohorts of luminal, TNBC and HER2-pos breast cancer patients treated in the neoadjuvant setting, where the mainstay pre-operative treatment is TaxAC-based therapy. This evidence concerns the gene ERBB2 and breast carcinoma.